Definitive Healthcare (NASDAQ:DH) Issues Q2 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its second quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.09 for the period, compared to the consensus EPS estimate of $0.09. The company issued revenue guidance of $63.7 million, compared to the consensus revenue estimate of $62.68 million. Definitive Healthcare also updated its FY 2024 guidance to 0.320-0.340 EPS.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH traded down $0.29 during midday trading on Friday, reaching $3.66. The company’s stock had a trading volume of 1,006,571 shares, compared to its average volume of 797,871. Definitive Healthcare has a fifty-two week low of $3.19 and a fifty-two week high of $11.60. The company has a market capitalization of $431.62 million, a P/E ratio of -2.26, a P/E/G ratio of 3.08 and a beta of 1.30. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.30 and a quick ratio of 2.30. The business’s fifty day simple moving average is $5.48 and its 200-day simple moving average is $7.09.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Tuesday, May 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. The business had revenue of $63.48 million during the quarter, compared to analyst estimates of $64.00 million. As a group, equities research analysts expect that Definitive Healthcare will post 0.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DH shares. William Blair reiterated an outperform rating on shares of Definitive Healthcare in a report on Tuesday, May 14th. Robert W. Baird reduced their target price on Definitive Healthcare from $8.00 to $6.00 and set a neutral rating on the stock in a report on Wednesday. Deutsche Bank Aktiengesellschaft reduced their target price on Definitive Healthcare from $10.00 to $7.00 and set a hold rating on the stock in a report on Thursday, May 9th. Morgan Stanley cut Definitive Healthcare from an overweight rating to an equal weight rating and reduced their target price for the stock from $11.50 to $9.00 in a report on Wednesday, May 8th. Finally, Barclays dropped their price target on Definitive Healthcare from $7.00 to $6.00 and set an equal weight rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Definitive Healthcare has a consensus rating of Hold and a consensus target price of $8.45.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.